We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+2.84%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.32B
AUM Growth
-$616M
Cap. Flow
-$442M
Cap. Flow %
-13.32%
Top 10 Hldgs %
35.56%
Holding
123
New
10
Increased
41
Reduced
28
Closed
11

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$31.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$25.3M
3
GPCR icon
Structure Therapeutics
GPCR
+$24.1M
4
UNH icon
UnitedHealth
UNH
+$22.1M
5
LLY icon
Eli Lilly
LLY
+$14.6M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$99.4M
2
PEN icon
Penumbra
PEN
+$47.9M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$44M
4
BSX icon
Boston Scientific
BSX
+$30.4M
5
IDXX icon
Idexx Laboratories
IDXX
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 97.3%
2 Consumer Staples 1.87%
3 Industrials 0.25%
4 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OSCR icon
51
Oscar Health
OSCR
$8.61B
$19.8M 0.6%
1,251,500
-858,500
-41% -$15.8M
NUVL
52
DELISTED
Nuvalent
NUVL
$19.4M 0.58%
255,989
+130,687
+104% +$9.3M
KRYS icon
53
Krystal Biotech
KRYS
$9.66B
$19.4M 0.58%
105,569
+1,600
+2% +$269K
INSP icon
54
Inspire Medical Systems
INSP
$1.74B
$17.4M 0.52%
130,000
-500
-0.4% -$94.6K
INZY
55
DELISTED
Inozyme Pharma
INZY
$16.5M 0.5%
3,698,374
+17,200
+0.5% +$83.4K
DYN icon
56
Dyne Therapeutics
DYN
$4.9B
$16.3M 0.49%
461,028
+9,204
+2% +$267K
DVAX
57
DELISTED
Dynavax Technologies
DVAX
$14.5M 0.44%
1,292,637
-382,837
-23% -$4.46M
PHVS icon
58
Pharvaris
PHVS
$2.44B
$14.2M 0.43%
756,931
+4,007
+0.5% +$81.5K
IMCR icon
59
Immunocore
IMCR
$1.73B
$14.2M 0.43%
419,030
-1,948,786
-82% -$99.4M
VERA icon
60
Vera Therapeutics
VERA
$2.36B
$13.8M 0.42%
381,192
+40,024
+12% +$1.59M
CRNX icon
61
Crinetics Pharmaceuticals
CRNX
$8.92B
$13M 0.39%
289,400
– –
PRTA icon
62
Prothena Corp
PRTA
$450M
$12.9M 0.39%
625,048
– –
OLK
63
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$12.7M 0.38%
500,000
-1,176,500
-70% -$28M
CRL icon
64
Charles River Laboratories
CRL
$12.8B
$12.4M 0.37%
60,250
+11,750
+24% +$2.66M
BMRN icon
65
BioMarin Pharmaceuticals
BMRN
$12.4B
$12.4M 0.37%
151,000
+2,168
+1% +$180K
FOLD
66
DELISTED
Amicus Therapeutics
FOLD
$12.1M 0.36%
1,218,580
+65,924
+6% +$677K
NVRO
67
DELISTED
NEVRO CORP.
NVRO
$11.6M 0.35%
1,381,500
+316,500
+30% +$3.37M
CGEM icon
68
Cullinan Oncology
CGEM
$1.14B
$11.5M 0.35%
+658,338
New +$14M
ELVN icon
69
Enliven Therapeutics
ELVN
$4.43B
$10M 0.3%
428,571
– –
JSPR icon
70
Jasper Therapeutics
JSPR
$23.6M
$9.18M 0.28%
404,335
– –
NVAX icon
71
Novavax
NVAX
$1.31B
$8.55M 0.26%
675,000
+137,375
+26% +$1.38M
ACCD
72
DELISTED
Accolade Inc
ACCD
$8.2M 0.25%
2,290,000
-1,250,000
-35% -$9.47M
FOCL
73
EDAP TMS S.A.
FOCL
$233M
$8.02M 0.24%
1,475,000
– –
SWTX
74
DELISTED
SpringWorks Therapeutics
SWTX
$7.53M 0.23%
+199,855
New +$8.41M
NMRA icon
75
Neumora Therapeutics
NMRA
$302M
$7.47M 0.22%
760,007
+113,889
+18% +$1.18M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Rock Springs Capital Management held 123 positions worth $3.32B, down 16% from $3.94B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $442M in Q2 2024, closing 11 positions and reducing 28 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Insmed worth $54.2M.

  • Rock Springs Capital Management's largest Q2 2024 buy was Insmed: 808,356 shares worth $54.2M.
  • Rock Springs Capital Management added most to Structure Therapeutics in Q2 2024, an estimated $24.1M increase.
  • Rock Springs Capital Management's biggest Q2 2024 reduction was Immunocore, cutting an estimated $99.4M.
  • Rock Springs Capital Management fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $44M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $3.32B portfolio in Q2 2024.
  • Rock Springs Capital Management opened 10 new positions and closed 11 in Q2 2024.
  • Rock Springs Capital Management's portfolio value fell 16% quarter-over-quarter to $3.32B.

Based on Rock Springs Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.